Abstract
ObjectivesTo determine the disease burden of acute lower respiratory tract disease (aLRTD) and its subsets (pneumonia, lower respiratory tract infection (LRTI) and heart failure) in hospitalised adults in Bristol, UK.SettingSingle-centre, secondary care hospital, Bristol, UK.DesignWe estimated aLRTD hospitalisations incidence in adults (≥18 years) in Bristol, UK, using two approaches. First, retrospective International Classification of Diseases 10th revision (ICD-10) code analysis (first five positions/hospitalisation) identified aLRTD events over a 12-month period (March 2018 to February 2019). Second, during a 21-day prospective review (19 August 2019 to 9 September 2019), aLRTD admissions were identified, categorised by diagnosis and subsequently annualised. Hospital catchment denominators were calculated using linked general practice and hospitalisation data, with each practice’s denominator contribution calculated based on practice population and per cent of the practices’ hospitalisations admitted to the study hospital.ParticipantsProspective review: 1322 adults screened; 410 identified with aLRTD. Retrospective review: 7727 adult admissions.Primary and secondary outcome measuresThe incidence of aLRTD and its subsets in the adult population of Southmead Hospital, Bristol UK.ResultsBased on ICD-10 code analysis, annual incidences per 100 000 population were: aLRTD, 1901; pneumonia, 591; LRTI, 739; heart failure, 402. aLRTD incidence was highest among those ≥65 years: 65–74 (3684 per 100 000 adults), 75–84 (6962 per 100 000 adults) and ≥85 (11 430 per 100 000 adults). During the prospective review, 410/1322 (31%) hospitalised adults had aLRTD signs/symptoms and annualised incidences closely replicated retrospective analysis results.ConclusionsThe aLRTD disease burden was high, increasing sharply with age. The aLRTD incidence is probably higher than estimated previously due to criteria specifying respiratory-specific symptoms or radiological change, usage of only the first diagnosis code and mismatch between case count sources and population denominators. This may have significant consequences for healthcare planning, including usage of current and future vaccinations against respiratory infection.
Funder
Pfizer, Inc
National Institute for Health Research
Reference27 articles.
1. Respiratory health and disease in Europe: the new European Lung White Book
2. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
3. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review;Torres;Respir Med,2018
4. European Lung White Book . Pneumonia. Available: https://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/pneumonia/#:~:text=pneumonia%20(VAP).-,Incidence,000%20cases%20are%20expected%20annually [Accessed 25 Apr 2021].
5. British Lung Foundation . Pneumonia statistics. Available: https://statistics.blf.org.uk/pneumonia [Accessed 25 Apr 2021].